Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Chemotherapy combined with trastuzumab and patuzumab is the standard neoadjuvant therapy for HER2 positive breast cancer patients. The survival rate of patients with pathological complete response (PCR) after neoadjuvant therapy was significantly better than that of patients with tumor residue, that is, non-PCR. Therefore, studies have confirmed that adjuvant therapy for patients with non-PCR after neoadjuvant chemotherapy can further improve the prognosis and survival of this population. However, the results of previous studies are based on trastuzumab target therapy in neoadjuvant therapy. Therefore, there are different recommendations for the current guidelines of adjuvant therapy after trastuzumab combined pertuzumab target neoadjuvant therapy. Patients with HER2 positive breast cancer who received trastuzumab and patuzumab based neoadjuvant therapy had invasive residual cancer in postoperative pathology. The effect of postoperative adjuvant therapy with trastuzumab and patuzumab or replacement of T-DM1 on survival.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznanie raka piersi HER2 dodatniego potwierdzonym biopsją w szpitalu
- •Stan zaawansowania choroby przed leczeniem: T1-T4, N0-N3, M0
- •Leczenie i operacja przeprowadzone w szpitalu z zachowaną dokumentacją
- •Otrzymanie co najmniej 4 cykli terapii celowanej (trastuzumab i pertuzumab) w połączeniu z chemioterapią przed operacją
- •Potwierdzenie w wyniku badania pooperacyjnego pozostałości raka w piersi lub przerzutów w węzłach chłonnych pod pachą
- •Podpisana zgoda na uczestnictwo w badaniu kohortowym
✗ Disqualifies
- •Brak pełnej dokumentacji klinicznej i badań obrazowych
- •Rak piersi z przerzutami na odległe narządy lub rak obu piersi
- •Nieokreślenie się do radykalnej operacji chirurgicznej
- •Otrzymanie innego schematu leczenia niż ustalony
Simplified criteria — AI translation
Trial details
- Last updated (source)
- November 20, 2024
- Sex
- No restrictions
Locations (1)
Peking University People's Hospital
Beijing, China
Trial contact
yuan peng, doctor
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.